Evidence map›Paper›PMID 32529991›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Identification of an Immune Score-Based Gene Panel with Prognostic Power for Oral Squamous Cell Carcinoma.

Su-Ning Huang, Guo-Sheng Li, Xian-Guo Zhou, Xiao-Yi Chen, Yu-Xuan Yao, Xiao-Guohui Zhang, Yao Liang, Ming-Xuan Li, Gang Chen, Zhi-Guang Huang and 5 more

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Frontiers in oncology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Identification of hub genes related to CD4Frontiers in genetics · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Su-Ning HuangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Guo-Sheng LiDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Xian-Guo ZhouResearch Department, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Xiao-Yi ChenDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Yu-Xuan YaoDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Xiao-Guohui ZhangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Yao LiangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Ming-Xuan LiDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Zhi-Guang HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Yi-Wu DangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Jing LiDepartment of Stomatology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Ping LiDepartment of Pathology, Affiliated Oral Hospital of Guangxi Medical University, Nanning, Guangxi, China (mainland).
Xiao-Zhun TangDepartment of Head and Neck Tumor Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).
Min-Hua RongResearch Department, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Oral squamous cell carcinoma (OSCC) is the sixth most prevalent cancer worldwide, with low 5-year survival rate. To identify novel prognostic markers for OSCC and determine the immune and stromal landscape of OSCC, a risk signature for OSCC patients was constructed in this study. MATERIAL AND METHODS Immune and stromal scores for OSCC samples from the Genomic Data Commons Data Portal were computed to delineate the tumor microenvironment landscape of oral cancer based on the Estimation of STromal and Immune cells in MAlignant Tumours using Expression data algorithm. An immune score-based risk signature was constructed by combining random forest and support vector machine methods. Correlation analysis of risk signature gene expression and immune cell infiltration was conducted, and the distinguishing power of individual signature genes was evaluated by analyzing receiver operating characteristics (ROC) curves. Differentially enriched pathways between high and low risk groups were investigated via gene set variation analysis. ROC curves were plotted for signature genes to examine their ability to distinguish the recurrence and survival status of OSCC patients from GSE84846. RESULTS An immune score-related risk signature composed of ARMH1, F2RL2, AC004687.1, COL6A5, AC008750.1, RAB19, CRLF2, GRIP2, and FAM162B performed well in the prognostic stratification of OSCC patients and could effectively distinguish their survival status. Lists of pathways, including cytokine-cytokine receptor interaction and cell adhesion molecules displayed remarkable differential enrichment between high and low risk OSCC patients. CONCLUSIONS An immune score-based risk signature constructed presently may be useful to decide appropriate treatment options for individual OSCC patients.

Indexed as

CytokinesDatabases, GeneticFemaleGene Expression ProfilingHumansImmune SystemLymphocytes, Tumor-InfiltratingMaleMouth NeoplasmsMultivariate AnalysisPrognosisProportional Hazards ModelsProtein Interaction MapsReceptors, CytokineRisk AssessmentRNA, MessengerCytokinesReceptors, CytokineRNA, Messenger

Identifiers

PMID32529991
PMCPMC7305786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.